BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21741247)

  • 1. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Maltais R; Fournier MA; Poirier D
    Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
    Tchédam-Ngatcha B; Luu-The V; Poirier D
    J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
    Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
    Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
    Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
    Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
    Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
    Maltais R; Luu-The V; Poirier D
    Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.
    Hu GX; Zhao B; Chu Y; Li XH; Akingbemi BT; Zheng ZQ; Ge RS
    Int J Androl; 2011 Apr; 34(2):138-44. PubMed ID: 20522127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
    Ngatcha BT; Luu-The V; Poirier D
    Bioorg Med Chem Lett; 2000 Nov; 10(22):2533-6. PubMed ID: 11086723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
    Bydal P; Auger S; Poirier D
    Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
    Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.